Publications

Abstract A113: Cachexia and Depression in Pancreatic Cancer (PC) Associate with Myeloid Inflammation and Tumor-Intrinsic Metabolic Stress

J Song, M Hilmi, C O'Connor, H Martirosova, J Schoenfeld, A Hilmi, ...

Abstract A125: Tumor cell plasticity, stromal rewiring, and clonal T cell expansion define response and resistance to combined PARP and PD-1 blockade (POLAR) in pancreatic cancer

M Hilmi, J Park, W Mckerrow, S Umeda, C O'Connor, Y Elhanati, ...

Abstract B047: DNA Damage Repair (DDR) Variants Beyond BRCA/PALB2 in Pancreatic Adenocarcinoma (PDAC): Evaluation of Significance

CA O'Connor, JW Lee, E Harrold, AL Richards, D Muldoon, ...

Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort

Keane F, O'Connor C, Moss D, Chou JF, Perry MA, Crowley F, Saxena P, Chan A, et al.

ASO Visual Abstract: Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma

AB Blair, SN Radomski, J Chou, M Liu, TC Howell, W Park, EM O’Reilly, ...

Clinical landscape of cell free DNA alterations in patients with advanced biliary tract cancer treated with targeted therapies.

R Thummalapalli, M Darmofal, K Seier, DN Khalil, HS Walch, J Shia, ...

Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer

Cowzer D, Darmofal M, Seier K, Thummalapalli R, Walch H, El Dika I, Khalil DN, Park W, et al.

Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma

Keane F, Saadat LV, O'Connor CA, Chou JF, Bowman AS, Xu F, Crowley F, Debnath N, et al.

Clinico-genomic characterization of PALB2-mutated pancreatic adenocarcinoma.

JW Lee, CA O'Connor, E Harrold, AL Richards, F Velez-Cortes, D Moss, ...

Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival

Varghese AM, Perry MA, Chou JF, Nandakumar S, Muldoon D, Erakky A, … Park W, …

Genomic analysis of paired primary and metastatic pancreatic ductal adenocarcinoma tumors.

CA McIntyre, V Rudneva, AL Richards, W Park, WR Jarnagin, ...

Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma

Judge SJ, Manin E, Chou J, Torphy RJ, McIntyre CA, Balachandran VP, D'Angelica MI, Drebin JA, et al.

Intrahepatic Cholangiocarcinoma: Recurrence Patterns, Genomics, and Survival

Chandra P, Song Y, Drill E, Wei AC, Kemeny N, Cercek A, Connell L, Harding J, et al.

Maximal Ablative Irradiation Because of Encasement for Patients with Potentially Resectable Locally Advanced Pancreatic Cancer: Final Results of Phase II MAIBE Trial

M Reyngold, A Wei, C Hajj, M Zinovoy, W Jarnagin, MI D'Angelica, ...

Mechanisms of resistance to the RAS (ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS (ON) combination therapies

S Kar, Y Zhuang, E Ahler, LP Lai, A Starodub, A Spira, SR Punekar, ...

Molecular and clinical determinants of targeted therapy (TT) outcomes in biliary tract cancer (BTC): Analysis of a prospectively maintained next generation sequencing (NGS …

D Cowzer, HS Walch, P Atri, F Shah, R Huq, DN Khalil, W Park, R Yeh, ...

Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy

Reyngold M, Schoenfeld JD, O'Reilly EM, Varghese AM, White C, Zinovoy M, Romesser PB, Wu AJ, et al.

OR19-06 Safety and Effectiveness of Sulfonylureas for Pancreas-Cancer Induced Metabolic Dysregulation

JH Flory, H Martirosova, E Tan, M Bakkar, M Goncalves, W Park, ...

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial

Park W, O'Connor C, Chou J, Hilmi M, Tarcan Z, Schwartz C, Larsen M, Chatila W, et al.

Resistance mechanisms to monotherapy RAS (ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC inform therapeutic combination strategies

I Aronchik, S Kar, Y Zhuang, E Ahler, LP Lai, V Seshadri, A Starodub, ...

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer

Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, Lihm J, …

Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with …

I Garrido-Laguna, BM Wolpin, W Park, NS Azad, AI Spira, A Starodub, ...

Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma

Blair AB, Radomski SN, Chou J, Liu M, Howell TC, Park W, O'Reilly EM, Zheng L, et al.

Target identification for antibody-drug-conjugate (ADC) therapy in biliary tract cancers (BTC)

A Dhyani, Z Tarcan, J Chou, R Thummalapalli, W Chatila, S Nag, E Rosen, ...

The Noncoding Mutational Landscape of Pancreatic Cancer Reveals Recurrent Somatic Mutations in Enhancer Regions

Hayashi A, Ho YJ, Makohon-Moore AP, Zucker A, Hong J, Umeda S, Karnoub ER, Huang J, et al.

1504MO Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination …

W Park, C O’Connor, J Chou, C Schwartz, M Larsen, A Varghese, K Yu, ...

1532TiP Zolbetuximab with gemcitabine+ nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized …

W Park, EM O'Reilly, CP Li, DY Oh, R Garcia-Carbonero, G Roth, ...

317P Targeted next generation sequencing (NGS) of cell free (cf) DNA in biliary tract cancer (BTC)

D Cowzer, K Seier, M Darmofal, P Shin, D Khalil, H Walch, J Shia, W Park, ...

708 Chemoimmunotherapy (ChemoIO) as treatment for pancreatic neuroendocrine carcinoma: survival outcomes and immunogenomic analysis

D Moss, C O’Connor, Z Tarcan, T Kim, MA Perry, R Thummalapalli, ...

Abstract B042: Clinical and molecular characterization of Lynch syndrome-associated pancreas adenocarcinoma (PDAC)

E Harrold, CA O'Connor, D Lin, A Gazzo, H Walch, M Ranganathan, ...

Abstract B045: Deep genomic and single cell molecular profiles define immunogenic pancreatic cancer

W Park, S Umeda, C O'Connor, H Zhang, R Sharma, A Richards, Y Zhu, ...

Abstract C074: Clinico-genomic characterization of N=2,460 pancreatic adenocarcinoma identifies KRASMUT dosage as prognostic of overall survival across …

AM Varghese, MA Perry, D Muldoon, S Nandakumar, A Erakky, B Nguyen, ...

Abstract C104: Dual primary pancreas cancers–Related or independent lesions?

JD Schoenfeld, H Sahan-Ozkan, N Bilani, MI D'Angelica, WR Jarnagin, ...

Abstract PR-06: Personalized RNA neoantigen vaccines induce long-lived CD8+ T effector cells in pancreatic cancer

P Guasp, Z Sethna, C Reiche, M Milighetti, N Ceglia, E Patterson, N Pang, ...

Adjuvant mFOLFIRINOX (mFFX) for resected pancreatic cancer (PC): Long term clinical and genomic outcomes.

F Keane, D Moss, CA O'Connor, M Perry, JF Chou, F Crowley, P Saxena, ...

Association of Sex and Obesity on Overall Survival in Patients Undergoing Upfront Surgery for Resectable Pancreatic Adenocarcinoma

SJ Judge, E Manin, J Chou, TP Kingham, VP Balachandran, ...

Automated real-world data integration improves cancer outcome prediction

Jee J, Fong C, Pichotta K, Tran TN, Luthra A, Waters M, Fu C, Altoe M, …

BNT321, a novel monoclonal antibody targeting sialyl Lewis A: Phase 1 monotherapy and combination with mFOLFIRINOX in patients with advanced CA19-9 expressing cancers.

EM O'Reilly, TM Bauer, EH Borazanci, M Pelster, AM Varghese, W Park, ...

Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma

McIntyre SM, Preston WA, Walch H, Sharib J, Kundra R, Sigel C, Lidsky ME, Allen PJ, et al.

Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer

McIntyre CA, Grimont A, Park J, Meng Y, Sisso WJ, Seier K, Jang GH, … Park W, …

Durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer (PDAC): Long-term outcomes and …

F Keane, R Tuli, CA O'Connor, C Schwartz, W Park, AM Varghese, ...

EGFR-directed antibodies promote HER2 ADC internalization and efficacy

Gupta A, Michelini F, Shao H, Yeh C, Drago JZ, Liu D, Rosiek E, Romin Y, et al.

Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome

Preston WA, Drill E, Boerner T, Gelfer R, Harding JJ, O'Reilly EM, Cercek A, Abou-Alfa G, et al.

Intrahepatic cholangiocarcinoma: Recurrence patterns, genomics and survival.

P Chandra, Y Song, EN Drill, ACC Wei, NE Kemeny, A Cercek, ...

Intrahepatic Cholangiocarcinoma: Recuurence Patterns, Genomics and Survival

P Chandra, Y Song, E Drill, AC Wei, N Kemeny, A Cercek, L Connell, ...

KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers

Gelfer R, Gulla A, Kalvin HL, Song Y, Harding J, Abou-Alfa GK, O'Reilly EM, Park W, et al.

Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer

O'Connor CA, Harrold E, Lin D, Walch H, Gazzo A, Ranganathan M, Kane S, Keane F, et al.

Morbidity and mortality in patients with stage IV pancreatic adenocarcinoma and acute cholangitis: Outcomes and risk prognostication

Singh I, Chou JF, Capanu M, Park J, Yu KH, Varghese AM, Park W, Zervoudakis A, et al.

Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors.

W Park, J Zhang, F Dayyani, J Shan, R Liu, R Guo, EM O'Reilly, Z Liu, ...

Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease

Keane F, Chou JF, Walch H, Schoenfeld J, Singhal A, Cowzer D, Harrold E, O'Connor CA, et al.